Clinical Trial · NCT03535545

Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients

Overview

The goal of this study is to investigate the safety of \[68Ga\]CBP8 and its efficacy to detect collagen deposition in pulmonary fibrosis.

Sponsor

Massachusetts General Hospital

Phase

Phase 1

Contacts

Sydney B Montesi, MD (CONTACT)

sbmontesi@partners.org

617 724 4030

Abimbola Akinniyi (CONTACT)

aakinniyi@mgb.org

781 513 0207

Sydney B Montesi, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

Drug / Compound

Isotope(s):

Target(s):

Ligand Class: Small Molecules

Eligibility

Age greater than 18 years
Be deemed healthy at screening visit as determined by the physician investigator or nurse practitioner, based on the following assessments at Screening: physical examination, medical history, and vital signs
Total enrollment for all groups will not exceed 100 subjects.
Group 1: Healthy subjects
Have the ability to give written informed consent;

Pregnant or breastfeeding (a negative quantitative serum hCG pregnancy test is required for females having child-bearing potential before the subject can participate);
eGFR of less than 30 mL/min/1.73 m2 within the past 90 days for group 4 subjects; history of chronic kidney disease for subjects in groups 1-3 and 5;
* Electrical implants such as cardiac pacemaker or perfusion pump;
Claustrophobic reactions;
Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, or steel implants ferromagnetic objects such as jewelry or metal clips in clothing;